National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance
Authors:
- Judith M. KramerJKJudith M. Kramer
- Bradley HammillBHBradley Hammill
- Kevin J. AnstromKAKevin J. Anstrom
- Donald FetterolfDFDonald Fetterolf
- Richard SnyderRSRichard Snyder
- John P. ChardeJCJohn P. Charde
- Barbara S. HoffmanBHBarbara S. Hoffman
- Nancy Allen LaPointeNLNancy Allen LaPointe
- Eric PetersonEPEric Peterson
- 1 September 2006
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 152 (3) , 454.e1-454.e8
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- From motives to results: Improving the effectiveness of quality improvementThe American Journal of Medicine, 2004
- Cost-Lowering Strategies Used by Medicare Beneficiaries Who Exceed Drug Benefit Caps and Have a Gap in Drug CoverageJAMA, 2004
- Get With the Guidelines for Cardiovascular Secondary PreventionArchives of internal medicine (1960), 2004
- Medication Errors in Hospitalized Cardiovascular PatientsArchives of internal medicine (1960), 2003
- The Prescription-Drug ProblemNew England Journal of Medicine, 2002
- beta Blockade after myocardial infarction: systematic review and meta regression analysisBMJ, 1999
- Under-Utilisation of ??-Blockers After Acute Myocardial InfarctionPharmacoEconomics, 1999
- Overview of Results of Randomized Clinical Trials in Heart DiseaseJAMA, 1988
- Six-Year Follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial InfarctionNew England Journal of Medicine, 1985
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985